# Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

> **NCT06331832** · — · NO_LONGER_AVAILABLE · sponsor: **IGM Biosciences, Inc.**

## Conditions studied

- Relapsed/Refractory Non-Hodgkin Lymphomas

## Interventions

- **BIOLOGICAL:** IGM2323

## Key facts

- **NCT ID:** NCT06331832
- **Lead sponsor:** IGM Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331832, "Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06331832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*